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Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production 
of autoantibodies to certain cellular macromolecules, such as the small nuclear 
ribonucleoprotein particles (snRNPs), which had been considered to be passive targets of the 
autoimmune response. SLE is also characterized by the increased expression of type I interferon 
(IFN), which appears to be associated with the development and severity of disease. Here, we 
show that specific, highly conserved RNA sequences within snRNPs can stimulate Toll-like 
receptors (TLRs) 7 and 8 as well as activate innate immune cells, such as plasmacytoid dendritic 
cells (pDCs), which respond by secreting high levels of type I IFN. SLE patient sera containing 
autoantibodies to snRNPs form immune complexes that are taken up through the Fc receptor 
 
 
 
RII and efficiently stimulate pDCs to secrete type I IFNs. These results demonstrate that a 
prototype autoantigen, the snRNP, can directly stimulate innate immunity and suggest that 
autoantibodies against snRNP may initiate SLE by stimulating TLR7/8.
 
Autoimmunity in systemic lupus erythematosus
(SLE) can attack virtually any organ in the
body. Nevertheless, the failure in immune toler-
ance that leads to disease in SLE is not general-
ized, but rather is highly specific: the earliest
targets of the autoimmune response are certain
nucleic acid–containing macromolecules, such
as chromatin and the U1 as well as other small
nuclear ribonucleoprotein particles (snRNPs).
Intriguingly, these autoantigens are clustered
together at the membranes of cells undergoing
apoptosis (for review see reference 1). Apoptosis
is generally considered to be a noninflammatory
type of cell death, and many studies have re-
ported tolerogenic effects of apoptotic cells.
On the other hand, injection of large numbers
of apoptotic cells into normal mice reportedly
induces autoantibody production (2). An asso-
ciation between apoptosis and autoimmunity
has been described in human SLE patients
who have reduced clearance of apoptotic cells
and increased circulating levels of nucleosomes
(3–5). Moreover, mice or humans with deficien-
cies in DNase or defects in the clearance of
apoptotic cells develop autoimmunity, provid-
ing increasing evidence for the hypothesis that
exposure to elevated levels of nucleosomes or
snRNPs can overcome self-tolerance (6–12).
This association of nucleosomal antigens
with autoimmunity has been hypothesized to
result from apoptosis-induced cleavage or other
alterations in the antigen structures, making
them immunogenic. However, this hypothesis
does not explain the observed abrogation of
immune tolerance in mice injected with apop-
totic cells, which implies the existence of some
simultaneous immune activation, perhaps trig-
gered by the apoptotic debris itself. In con-
sidering possible mechanisms through which
apoptotic  material could conceivably induce
autoimmunity, it is intriguing that phagosomes
containing apoptotic cell particles are adja-
cent to Toll-like receptor (TLR)7 (13), which
is known to be activated by single-stranded
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RNA molecules (14–16). Because the snRNPs within apop-
totic blebs contain single-stranded RNA, they are potential
TLR7 ligands.
In this study, we tested whether the U1 snRNP, a proto-
type target of the autoimmune response, could stimulate im-
munity directly. We demonstrate that the U1 snRNP can
stimulate TLR7, leading to IFN-
 
 
 
 secretion from plasmacy-
toid DCs (pDCs), and TLR8, leading to TNF-
 
 
 
 secretion
from monocytes. These stimulatory effects require the RNA
component of the particle and can be reproduced by syn-
thetic oligoribonucleotides (ORNs) as short as nine bases
containing certain conserved U-rich autoantigen or autoanti-
body binding sites from the U1 or other snRNAs. Stimula-
tion requires transfection or the formation of immune com-
plexes comprised of anti-RNP antibodies from SLE patients
and snRNP, which pDCs appear to take up through the
Fc
 
 
 
RII. Inhibitory oligodeoxynucleotides (ODNs) and “an-
timalarial” small molecules are shown to block these immuno-
stimulatory effects with potential therapeutic implications.
 
RESULTS
Immune stimulation by purified U1 snRNP through TLR7
 
Apoptotic cells or apoptotic material in the presence of some
SLE sera has been reported to induce PBMC secretion of
IFN-
 
 
 
, which was attributed to the formation of stimulatory
immune complexes because stimulation reportedly required
the addition of SLE serum (17). In preliminary studies, we
found that apoptotic cell debris induced IFN-
 
 
 
 secretion
from normal human PBMCs, even in the absence of SLE se-
rum (not depicted). To test the possibility that U1 snRNP
within the apoptotic material may be responsible for this
stimulatory effect, human PBMCs were incubated with U1
snRNP, revealing a dose-dependent increase in IFN-
 
 
 
 and
TNF-
 
 
 
 secretion (Fig. 1 A). Mammalian U1 snRNP con-
sists of a complex of 10 different proteins and the 165-nucle-
otide U1 RNA molecule (18). The stimulatory activity of
U1 snRNP only required the U1 RNA because treatment
with RNase, but not proteinase, led to complete loss of
IFN-
 
 
 
 secretion (Fig. 1 C). Highly purified U1 snRNA
stimulated dose-dependent production of IFN-
 
 
 
 (Fig. 1 D).
However, the level of IFN-
 
 
 
 secretion induced by the U1
snRNA was lower than that from the snRNP, suggesting
the possibility that the protein component of the snRNP
may in some way enhance the immune effect of the RNA.
In contrast, total cellular RNA isolated from the human T
cell line Jurkat induced little or no IFN-
 
 
 
 secretion, even at
RNA concentrations as high as 100 
 
 
 
g/ml (not depicted).
The high level of snRNP-induced IFN-
 
 
 
 secretion sug-
gested the potential involvement of pDCs, which are the
primary IFN-
 
 
 
–secreting cells in response to viral infection
(19). Double-stranded RNAs activate TLR3 (20), and sin-
gle-stranded RNA molecules have been reported to stimu-
late murine TLR7 and human TLR8 (14–16). Of these,
only TLR7 is expressed within pDCs. Enrichment of pDCs
or monocytes from human PBMCs demonstrated snRNP-
mediated stimulation of IFN-
 
 
 
 production from the pDC-
enriched (CD123
 
 
 
 
 
CD14
 
 
 
), but not the monocyte-enriched
(CD123
 
 
 
 
 
CD14
 
 
 
) or double-negative (CD123
 
 
 
 
 
CD14
 
 
 
),
Figure 1. U1 snRNP induces type I IFN production. (A) Human PBMCs 
were stimulated with U1 snRNP (concentration given for total RNA plus 
protein) complexed to DOTAP (DO), 100 ng/ml LPS, or DOTAP alone, and 
cytokines were measured. Med, medium control. (B) SDS page of U1 
snRNP, 4% stacking, 13.5% separation gel under reducing conditions, and 
Coomassie blue staining. Lane UF, RNP/Sm antigen, 8.8  g protein; lane 
M, SigmaMarker, wide molecular weight range. (C) PBMCs were cultured 
with 20  g/ml snRNP, 10  g/ml poly rI:rC (pIC), snRNP, or poly rI:rC pre-
treated with RNase A or snRNP pretreated with proteinase K complexed to 
DOTAP. (D) PBMCs were stimulated with U1 snRNP or U1 snRNA com-
plexed to DOTAP or DOTAP alone. The stimulatory properties of U1 snRNP 
or snRNA required the presence of an uptake enhancer (not depicted). All 
experiments show mean   SEM of one representative out of two or more 
experiments, each with at least three to six donors. 
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fraction (Fig. 2 A). A lower production of IFN-
 
 
 
 induced
by the U1 snRNP in the pure pDCs may reflect some bene-
ficial effect of cell–cell interactions, which will need to be
elucidated in further studies. Experiments with HEK293
cells stably transfected with human TLR8 and an NF-
 
 
 
B
luciferase reporter construct demonstrated only modest
TLR8-mediated signaling induced by the U1 snRNPs (U1
snRNP at 100 
 
 
 
g/ml: fold induction luciferase activity: 2.02 
 
 
 
0.69; R-848 at 25 
 
 
 
M: 11.21 
 
 
 
 0.84), perhaps due to a rel-
atively low sensitivity of TLR8 as described previously (21).
Surprisingly, we were unable to demonstrate direct stimula-
tion of TLR7 by snRNPs in stably transfected HEK293 cells
(not depicted), despite finding strong stimulation using the
ligand R-848 (21). As an alternative approach to testing for
possible TLR7 activation, we used the murine macrophage-
like cell line RAW246, which expresses TLR7 but no func-
tional TLR8. U1 snRNP stimulated TNF-
 
 
 
 production in
these cells (Fig. 2 B). Although these experiments on human
pDCs and murine RAW246 cells suggested that the U1
snRNP can stimulate TLR7, they did not indicate whether
TLR7 was required for the innate immune response to
snRNP. To more directly address this question, we com-
pared the ability of snRNP to induce IFN-
 
 
 
 and IL-12 se-
cretion in DCs from Fms-like tyrosine kinase 3 ligand
(Flt3L)-induced bone marrow cultures of wild-type mice or
mice genetically deficient in TLR7 (Fig. 2, C and D). These
experiments revealed that TLR7 is almost completely re-
quired for the snRNP-induced IFN-
 
 
 
 response and is im-
portant but not absolutely required for the snRNP-induced
IL-12 response. As expected, TLR7 was absolutely required
for responses to the TLR7 ligand R-848 but was not re-
quired for responses to the TLR9 ligands CpG 2216 and
CpG 1668 (Fig. 2, C and D). Thus, the snRNPs directly
stimulate TLR7 within murine immune cells, but additional
stimulation of other pathways may contribute to the low but
consistent IL-12 response in TLR7
 
 
 
/
 
 
 
 cells.
 
Sequence-specific immune activation
 
The Sm proteins are common to all U snRNPs, whereas the
U1-70K, U1-A, and U1-C proteins are specific to U1. The
U1 snRNA forms four hairpin loops (loop I to IV), the
stems of which are connected by a four-way junction. Stem/
loop IV is linked to this junction by a short single-stranded
sequence to which the Sm proteins bind. U1-70K and U1-A
bind directly to U1 RNA stem/loop I and II, respectively
(18). To determine whether any of these U1 RNA se-
quences are particularly responsible for the U1 snRNA–
induced immune stimulation, we synthesized ORNs com-
prising the binding sites for the U1-70K (1176; Table I),
U1-A (1171), or Sm (1170) proteins (22) and/or containing
autoantibody binding sites (1170 and 1171; references 23
and 24). U1 snRNA–derived ORNs (1170, 1171, and 1176)
stimulated the secretion of IFN-
 
 
 
, TNF-
 
 
 
, and IL-12p40 in
a dose-dependent fashion, comparable to a previously re-
ported immune stimulatory sequence derived from the U5
region of HIV-1 RNA (Fig. 3, A and C; reference 15).
Autoantibodies frequently target Ro RNPs, which consist
of at least one of two polypeptides (Ro and La) associated with
one of four small cytoplasmic RNAs (hY1, hY3, hY4, and
hY5; references 25 and 26). ORNs 1172 and 1563 derived
from the hY5 and hY3 RNA, both containing the binding site
for the La autoantigen, stimulated IFN-
 
 
 
 production from hu-
man PBMCs (Fig. 3, A and B). Interestingly, the La binding
site of all human hY RNAs consists of U-rich regions pre-
ceded by at least one C or G (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20051696/DC1). Simi-
lar sequences can be found within the 3
 
 
 
 regions of human
small RNAs synthesized by the RNA polymerase III (Table
S1), suggesting that such endogenous RNAs may also exert
immune stimulatory effects. Moreover, some U1 snRNA–
derived ORNs failed to induce substantial cytokine produc-
tion (ORNs 1271 and 1272; Fig. 3 D). On examination of the
U1 snRNA ORN sequences, we noted that the stimulatory
ones (ORNs 1170, 1171, 1174, and 1176) contained G/U-
rich domains, but the nonstimulatory ones (ORNs 1271 and
1272) had only G-rich regions (Table I). To test the hypothesis
that immune stimulation required these G/U-rich domains, we
Figure 2. TLR7 is required for the immune response to U1 snRNP. 
(A) Human PBMCs, CD14-enriched PBMCs (CD14 ), CD14- and CD123-
depleted PBMCs (CD14  CD123 ), or CD123-enriched PBMCs (CD123 ) 
were stimulated with 20  g/ml U1 snRNP complexed to DOTAP (DO), 
and cytokines were measured. Med, medium control. Mean   SEM of 
three donors. (B) Murine RAW246 macrophages were stimulated for
16 h with 20  g/ml U1 snRNP complexed to DOTAP, 1.0  M CpG ODN 
1826, or DOTAP alone. (C–D) Murine DCs derived from Flt3L-induced 
bone marrow cultures from C57/B6 wild-type or TLR7 /  mice were 
cultured with 20  g/ml U1 snRNP or ORN 1170 or ORN 1177 alone or 
complexed to DOTAP, 2  g/ml R-848, or 1  M CpG ODN 1668 or ODN 
2216. Percentage of pDCs was 44% for wild type and 45% for TLR7 /  
bone marrow (measured as CD45RA and CD11chigh cells). 
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Figure 3. U1 snRNA ORNs stimulate cytokine production and TLR8 
signaling. PBMCs were stimulated with DOTAP alone (DO) or complexed 
to ORN at the indicated concentrations (A, E, and H) at 0.25  M (C, D 
and F) or 0.5  M (B and D), and cytokines were measured. Med, medium 
control. Panels show one representative of up to three independent 
experiments (each with three donors; mean   SEM) or one representative 
of three donors (E and H; mean   SD). (I) hTLR8-HEK293 cells were incubated 
with 3  M ORN complexed to DOTAP, 10  M R-848, or 10  M CpG ODN 
for 16 h. Stimulation indices represent -fold NF- B activation compared 
with transfected, nonstimulated cells. (J) hTLR8-HEK293 cells were incubated 
with 10  M ORN complexed to DOTAP for 16 h.
 
synthesized ORN 1177, in which all U and G nucleotides of
ORN 1170 were replaced by A. ORN 1177 stimulated mini-
mal IFN-
 
 
 
 or other cytokine production (Fig. 3, A and C, and
not depicted). In contrast, introducing a G/U-rich sequence
derived from the previously described HIV-1 RNA sequence
(15) into ORN 1170 led to an enhancement of IFN-
 
 
 
 secre-
tion (Fig. 3 E). These results confirm a requirement for U1-
derived G/U-rich sequences for the stimulatory effects.
The Sm protein binding sites (as well as the hY RNA La
binding sites) differ from the previously described G/U-rich
TLR7-activating sequences. The U1 Sm binding site consists
of an adenosine at the 5
 
 
 
 side of an oligo(U) tract containing
just one guanosine (Table S1; references 27 and 28). Never-
theless, ORN with only this highly conserved 9-mer U-rich
sequence from the U4 or U1 Sm binding sites (ORNs 1330
and 1332, respectively) stimulated IFN-
 
 
 
 (Fig. 3 F) and TNF-
 
 
 
(not depicted) production from PBMCs. The U specificity of
these effects was confirmed by the inactivity of control ORN
with the same sequence but a U to C exchange (ORNs 1331
and 1333). The Sm protein binding site on the various sn-
RNAs is highly conserved throughout different species (Table
S1), suggesting a general potential for immune stimulatory ef-
fects of snRNPs across these species. These results expand the
range of ORNs known to activate TLR7 and TLR8 to
U-rich sequences containing as little as one guanosine.
The U1 snRNP is only slightly cleaved during apoptosis,
and cleavage of the U1 snRNA is very specific. Only the
first five to six 5
 
  
 
nucleotides protruding from the U1 sn-
RNP complex are removed. ORN 1300 consisting of just
the 12 5
 
  
 
snRNA nucleotides stimulated IFN-
 
 
 
 production
from human PBMCs (Fig. 3 G and Table I). ORN 1302
containing only six 5
 
 
 
 snRNA nucleotides was minimally
stimulatory compared with ORNs with nine or more nucle-
otides, demonstrating length dependence of the RNA-
mediated effects. Another U1 snRNA–derived ORN derived
from the 5
 
 
 
 single-stranded region of loop IV (ORN 1174)
contains a 5
 
 
 
 G/U-rich sequence. To determine the influ-
ence of position of the G/U-rich sequence on immune
stimulation, the 5
 
 
 
 sequence (5
 
 
 
-UUUGUG-3
 
 
 
) was shifted
stepwise to the 3
 
 
 
 end, demonstrating a position-dependent
effect of ORN-mediated cytokine production favoring the
3
 
 
 
 end (Fig. 3 H).
 
Stimulation of TLRs, pDCs, and monocytes by ORNs
 
Previous studies have demonstrated that in addition to the
well-established stimulation of TLR3 by double-stranded
RNA, a variety of single-stranded RNAs can activate mouse
immune cells through TLR7 and human immune cells
through TLR8, but the question of whether the effects are
sequence-specific or not has been controversial (14, 15,
29, 30). To investigate the involvement of TLRs in the
snRNA-derived ORN-mediated cytokine production,
HEK293 cells stably transfected with human TLR8 and an
NF-
 
 
 
B luciferase reporter construct were incubated with 
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various ORNs, the TLR9 ligand CpG ODN 2006, or the
TLR7/8 ligand R-848 (21). All of the U-rich ORNs acti-
vated TLR8, but the mutated control ORNs 1177, 1331,
and 1333 did not (Fig. 3, I and K), demonstrating sequence
dependency of TLR8-mediated NF-
 
 
 
B activation. In con-
trast to the U1 snRNP, all ORN immune stimulatory effects
 
Table I.
 
Oligonucleotides (ONs)
 
ON Sequence 5
 
 
 
–3
 
 
 
Length Position/description S
1170 GGACUGCGUUCGCGCUUUCC 20 Stem/Loop IV  
1171 GGCUUAUCCAUUGCACUCCGGA 22 Stem/Loop II  
1172 GACUAGCUUGCUGUUU 16 3  Stem hY5 RNA  
1174 UUUGUGGUAGUGGGGGACUG 20 Single-stranded region 5  loop IV U1 RNA  
1176 ACGAAGGUGGUUUUCCCAG 19 3  Stem I  
1177 AAACAACAAACACACAAACC 20 U, G →A 1170  
1271 ACCUGGCAGGGGAGA 15 5  Stem I  
1272 CCCAGGGCGAGGC 13 5  Stem II  
1274 GGACUGCGUUGUGGCUUUCC 20 ORN 1170 with G/U-rich region  
1300 GAUACUUACCUG 12 5  end U1 snRNA  
1302 GAUACU 6 5  end U1 snRNA upon apoptotic cleavage  
1330 AAUUUUUGA 9 Sm Site U4 snRNA  
1331 AACCCCCGA 9 Sm Site U4 snRNA U to C  
1332 AAUUUGUGG 9 Sm Site U1 snRNA  
1333 AACCCGCGG 9 Sm Site U1 snRNA U to C  
1337 GUAGUGUUUGUGGGGGACUG 20 ORN 1174 5  UUUGUG shift center  
1338 GUAGUGGGGGACUGUUUGUG 20 ORN 1174 5  UUUGUG shift 3  end  
1563 GACUAGCCUUU 11 3  Stem hY3 RNA  
1668 (DNA) TCCATGACGTTCCTGATGCT 20 Murine CpG B-Class  
1826 (DNA) TCCATGACGTTCCTGACGTT 20 Murine CpG B-Class  
2006 (DNA) TCGTCGTTTTGTCGTTTTGTCGTT 24 CpG B-Class  
2088 (DNA) TCCTGGCGGGGAAGT 15 S-Class  
2216 (DNA) GGG-G-G-A-C-G-A-T-C-G-T-CGGGGG 19 CpG A-Class (  indicates phosphodiester linkages)  
2395 (DNA) TCGTCGTTTTCGGCGCGCGCCG 22 CpG C-Class  
All ONs have phosphorothioate backbones for nuclease resistance, except as indicated for ON 2216, and all are RNA with the exception of the last six, which are DNA as indicated. 
S   or   indicates stimulatory capacity of the ONs.
Figure 4. U1 snRNA ORNs induce cytokine secretion from purified 
human monocytes, pDCs, or mDCs. Human PBMCs, CD14-enriched PBMCs 
(CD14 ), CD14- and CD123-depleted PBMCs (CD14  CD123 ), CD123-
enriched PBMCs (CD123 ), CD19- and CD1c-depleted PBMCs (CD14  
BDCA-1 ), or CD1c-enriched PBMCs (BDCA-1 ) were stimulated with 0.5 
 M ORN 1170 and/or 1271 complexed to DOTAP (DO), DO alone, or 0.5  M 
CpG ODN and tested for (A) IFN- , (B and D) TNF- , and (C) IL-12p40 secre-
tion. Mean   SEM of two (A) or three (B–D) donors. Med, medium control.RNA-MEDIATED TLR ACTIVATION | Vollmer et al. 1580
were abolished in DCs generated from TLR7 /  mice (Fig.
2, C and D), confirming that their activity on murine im-
mune cells depended entirely on this innate immune recep-
tor. Additional studies will be needed to understand the
mechanism of the difference between ORN- and snRNP-
mediated immune effects in wild-type versus TLR7 /  cells.
None of these ORNs induced detectable TLR7-dependent
signaling in transfected HEK293 cells, despite appropriate
positive controls (not depicted), which suggests either that
the HEK293 cells may lack some cofactor specifically re-
quired for ORN-induced activation of TLR7, or that the
NF- B luciferase reporter used for these assays might be in-
sufficient to detect the ORN effects. Additional studies will
be required to resolve this question.
To determine whether the ORNs would stimulate
RNA-responsive TLRs in primary immune cells, mono-
cytes (TLR8 ), myeloid DCs (mDCs) (TLR8 ), or pDCs
(TLR7 ) were isolated from human PBMCs and cultured
with ORN 1170 or ORN 1271, or the TLR9 agonist CpG
ODN 2395 (31). PBMCs and CD123  pDCs were highly
stimulated by ORN 1170 or CpG ODN 2395 to secrete
IFN- , whereas CD14  monocytes or CD123-/CD14-
depleted PBMCs were not, and the control ORN 1271 was
inactive (Fig. 4 A). This indicated the direct ability of the
U-rich ORN to activate the pDCs through TLR7. Con-
versely, ORN 1170 induced high levels of TNF-  produc-
tion from PBMCs, mDCs, and CD14  monocytes as well as
high IL-12 production from mDCs, indicating the direct
ability of the U-rich ORN to activate monocytes and mDCs
through TLR8 (Fig. 4, B–D).
Inhibition by chloroquine and suppressive ODNs
Chloroquine and related compounds inhibit CpG DNA–
driven signaling through TLR9 (32). Chloroquine inhibited
IFN-  secretion from PBMCs stimulated by U1 snRNP,
ORN 1170, or CpG ODN 2395 in a dose-dependent man-
ner (Fig. 5 A). Compared with the U1 snRNP, IFN-  secre-
tion induced by the ORN required higher chloroquine con-
centrations for inhibition, perhaps because of the nuclease-
resistant phosphorothioate backbone of the ORN. However,
chloroquine failed to inhibit poly rI:rC–mediated IFN-  pro-
duction, even at high concentrations (Fig. 5 B). Because
poly rI:rC is a TLR3 ligand, this result points to a difference
in the mechanism of TLR3-mediated immune stimulation
compared with the chloroquine-sensitive effects mediated
through TLR7–9 and suggests that the chloroquine-sensitive
effects of the snRNP and ORN are not mediated through
TLR3. The specific inhibitor of the endosomal and lysosomal
V-type ATPase, bafilomycin A1, had a similar inhibitory ef-
fect on IFN-  secretion by snRNP or ORN to that of chlo-
roquine (see Fig. 7 B and not depicted). Certain suppressive
G-rich ODNs (“S-Class”) inhibit immune activation elicited
by CpG DNA and can be used to treat lupus in animal mod-
els (33). The S-Class ODN 2088 suppressed snRNP-, ORN
Figure 5. Chloroquine and S-Class ODN 2088 block the immune 
stimulatory effects of U1 snRNP and U1-derived ORNs. (A and B) Human 
PBMCs were stimulated with medium (Med), 10  g/ml U1 snRNP complexed 
to DOTAP (DO), 0.5  M CpG ODN 2395, 0.125  M ORN 1170 complexed to 
DOTAP, or 30  g/ml poly rI:rC (pIC) alone or in the presence of the indicated 
concentrations of chloroquine (CQ) or (C and D) S-Class ODN 2088, or 
with 10  g/ml of ODN 2088 alone. ODN 2088 also inhibited ORN-induced 
TNF-  secretion (not depicted). Mean   SEM of one representative out of 
two to three independent experiments (n   3 donors).
Table II. Autoantigen-precipitating activity of SLE patient sera
Patient RNP Sm Ro60 La Core histones RNAPII Su DNA-PK OJ
6564 X
6567
6569
6571 X X
6574 X X X X
6575 X
6576 X
6579 X X X
6622 X X X X
6627 X
6628 X X
6630 X X
6633 X
6642 X X
Immunoprecipitations were performed as described in Materials and methods, and as 
shown in Fig. 6 D. X indicates a positive result as defined for the following 
specificities: RNP, immunoprecipitation of A, B /B, C, D, E, F, and G, but not U5 200K 
protein; Sm, immunoprecipitation of A, B /B, C, D, E, F, and G plus U5 200K protein; 
Ro60, immunoprecipitation of 60 kD protein; La, immunoprecipitation of 45 kD 
protein; Core histones, immunoprecipitation of H2A/H2B plus unidentified band; 
RNAPII, immunoprecipitation of RNA polymerase II, two largest subunits; DNA-PK, 
immunoprecipitation of DNA-PKcs, Ku70, and Ku80 proteins; OJ, 
immunoprecipitation of multiprotein complex.JEM VOL. 202, December 5, 2005 1581
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1170–, and CpG ODN 2395–mediated IFN-  production
(Fig. 5, C and D), demonstrating that its inhibitory effects are
not limited to TLR9, but extend to TLR7.
CD32-dependent activation of pDCs by lupus sera 
and snRNPs
Immune stimulation by the purified snRNPs and synthetic
ORNs required their delivery with cationic lipids. We hy-
pothesized that in SLE patients, delivery of the immune
stimulatory U-rich RNA sequences could be facilitated if
the sequences were within immune complexes. To test this
hypothesis, we mixed purified snRNP with 14 separate SLE
patient sera containing various autoantibody specificities
(Table II and Fig. 6 D). Some of the SLE patient sera alone
induced IFN-  secretion from normal human PBMCs (Fig.
6, A and E). However, all of the sera that contained at least
Figure 6. SLE patient sera containing anti-RNP antibodies combine 
with purified U1 snRNP to induce IFN-  production. (A and B) Normal 
human PBMCs were stimulated in 87.5% culture medium with 12.5% of 
eight (A–C) or six (E and F) SLE patient sera without (A and E) or with (B and 
F) 10  g/ml U1 snRNP, or were pretreated with 500 IU/ml IFN- 2b (C and F) 
and assayed for IFN- . Controls included medium (Med) and DOTAP (DO) 
alone or with 10  g/ml U1 snRNP. Mean   SEM for three donors. (D) Eight 
coded SLE patient sera (for all sera see Table II) were tested for the presence 
and level of various autoantibodies, including RNP components by radio-
immunoprecipitation. Assessment of anti-RNP levels within these eight sera 
revealed two strongly positive sera (6571 and 6574), two moderate positive 
(6564 and 6579), and one very weak positive (6576), with the others negative.
Figure 7. U1 snRNP and anti-RNP  SLE patient sera stimulate 
RNA-dependent IFN-  production inhibited by chloroquine and 
bafilomycin. (A) SLE patient sera 6622 and 6628 with 10  g/ml U1 
snRNP pretreated with RNase A were used to stimulate human PBMCs 
as described in Fig. 6. Mean   SEM for three donors. (B) Normal human 
PBMCs were stimulated with SLE serum 6642 alone or with 10  g/ml U1 
snRNP or 0.5  M CpG ODN 2395 in the presence or absence of 1.0 or 
5.0  M chloroquine (CQ) or 500 nM bafilomycin (Baf). Controls included 
chloroquine or bafilomycin alone or 0.5  M ORN 1170. Mean   SEM for 
two donors.RNA-MEDIATED TLR ACTIVATION | Vollmer et al. 1582
moderate levels of immunoprecipitating anti-RNP antibody
induced strong IFN-  production when supplemented with
purified U1 snRNP (Fig. 6, B and F). Preincubation of
PBMCs with IFN-  led to increased IFN-  secretion by these
anti-RNP sera that was more than additive above the level
of IFN- 2 added to the cultures (Fig. 6, C and F). Stimula-
tion of IFN-  production in the presence of snRNPs was
decreased to levels of roughly those observed in the absence
of snRNP upon RNase treatment (Fig. 7 A). Chloroquine
or bafilomycin severely diminished IFN-  production (Fig.
7 B). U1 snRNP alone as well as sera supplemented with sn-
RNP stimulated monocyte CD80 expression, indicating the
maturation of these cells (Fig. 8 A). Positive SLE patient sera
combined with snRNPs stimulated IFN-  production from
PBMCs or purified pDCs to a similar level as that induced
by snRNPs or ORN 1170 transfected with DOTAP (Fig. 8
B). The IgG receptor CD32 (Fc RII) binds avidly to IgG
present in immune complexes and is expressed on human
pDCs where it mediates IFN-  production by SLE patient
serum combined with apoptotic cells or DNA immune
complexes (34, 35). By adding blocking antibodies against
CD16 (Fc RIII) or CD32, we found that only anti-CD32
antibody blocked the IFN-  secretion from purified pDCs
(Fig. 8 C). In contrast, IFN-  secretion stimulated by CpG
ODN 2395 was not affected by the anti-CD32 antibody.
Therefore, CD32 appears to be responsible for delivering
RNA immune complexes to one or more pDC intracellular
compartments containing TLR7.
DISCUSSION
There has been much interest in understanding why the au-
toimmune response in SLE is targeted selectively at certain
nucleic acid–containing macromolecules that are concen-
trated within apoptotic cellular blebs. A popular hypothesis
has been that these autoantigens become immunogenic dur-
ing apoptosis, which then may drive the autoimmune re-
sponse. The present results demonstrate that the prototype
autoantigen U1 snRNP, which is highly represented within
apoptotic cells, is not simply a passive target of the autoim-
mune response, but rather is directly immune stimulatory
when delivered into innate immune cells expressing either
TLR7 or TLR8. Delivery of U1 snRNP can occur either
via transfection or more physiologically by the uptake of
snRNP-containing immune complexes formed by SLE pa-
tient sera containing anti-RNP antibody through Fc RIIa
(CD32) present on pDCs. The stimulatory effects require
the RNA component of the particle and appear to be medi-
ated predominately through TLR7. A modest response is
seen in TLR7 /  mice lacking functional TLR8 (15), sug-
gesting an additional involvement of other immune stimula-
tory pathways. Immune activation could be reproduced by
purified U1 snRNA or by synthetic ORNs containing cer-
tain conserved U-rich autoantigen or autoantibody binding
sites from the U1 snRNAs or hY RNAs. Some of these
U-rich regions are conserved across various small RNAs and
different species, indicating that they may stimulate TLR7-
mediated immune responses, at least when present in or
reaching TLR7-containing compartments. Stimulation by
synthetic ORNs was mediated by G/U- or U-rich se-
quences containing as little as one guanosine and was depen-
dent on the length and position of the U-rich sequence.
Type I IFN promotes T cell responses (36) and induces
autoimmunity in up to 20% of humans treated with recom-
binant IFN-  (for review see reference 37). Increased ex-
pression of type I IFN occurs in the pDCs of lupus patients,
is associated with disease severity, and may contribute to dis-
ease development (38–41), thereby linking pDC activation
to SLE pathogenesis. Activation of the IFN-  pathway in
SLE patients is significantly associated with the presence of
certain autoantibody specificities, especially anti-RNP and
other RNA-associated factors, but not with antiphospholipid
antibodies (40). Human pDCs express TLR7, but not the
other RNA-activated TLRs, TLR3 or TLR8 (42, 43), that
localize preferentially near phagosomes containing apoptotic
Figure 8. Anti-RNP  SLE patient sera and U1 snRNP stimulate 
monocyte maturation and CD32-dependent IFN-  production from 
pDCs. (A) PBMCs were stimulated with SLE patient sera 6622 and 6628 
with 10  g/ml U1 snRNP, snRNP complexed to DOTAP (DO), or with 0.5  M 
CpG ODN 2395 as described in Fig. 6. CD80 expression on CD14  cells was 
measured by flow cytometry. Mean   SEM for two donors. (B) Whole 
PBMCs, CD14- and CD123-depleted PBMCs (CD14  CD123 ), or purified 
CD123  pDCs were cultured as shown. Mean   SEM for three donors. 
(C) Purified CD123  pDCs were incubated with SLE patient sera 6571 (or 
6574; not depicted) and 10  g/ml U1 snRNP, or 0.5  M of positive control 
CpG ODN 2395   5  g/ml antibody to CD16 or CD32. Mean   SD for one 
out of two experiments.JEM VOL. 202, December 5, 2005 1583
ARTICLE
particles (13). Therefore, inappropriate or excessive activa-
tion of TLR7 by U-rich RNA sequences within snRNP
could trigger the observed activation of the IFN-  pathway
in SLE patients. All these TLRs are in endoplasmic reticu-
lum or endosomal/lysosomal compartments (44), which ex-
plains the requirement we found for transfection of the puri-
fied snRNPs or snRNA-derived ORNs. Our results suggest
a possible mechanism for the observed linkage between de-
fects in apoptotic cell clearance and SLE. We propose that
under normal physiologic conditions, the small amounts of
apoptotic cellular debris might be cleared too rapidly to acti-
vate the TLR pathways. However, in susceptible individuals
with defective clearance, or under such abnormal conditions
as during an immune response to a virus or other agent, the
apoptotic debris in the form of immune complexes might
be taken up by pDCs at high enough levels so that the
U-rich sequences within the enclosed snRNP activate TLR7,
thereby initiating type I IFN production and autoimmunity.
In light of our results, the recently observed association of
EBV infection with SLE could be explained by the homol-
ogy and antigenic cross reactivity between the EBV nuclear
antigen 1 and the snRNP and other autoantigens that are as-
sociated with apoptotic blebs (45). Molecular mimicry be-
tween EBV nuclear antigen 1 and snRNP or other lupus au-
toantigens would lead to the production of autoantibodies
reactive with apoptotic debris. Once an individual made au-
toantibodies that cross reacted with any component of the
apoptotic cells or snRNP, these would form immune com-
plexes that enhance the uptake of the nucleosome and sn-
RNP nucleic acids through Fc RII on the pDCs. The au-
toimmune process would then become self-perpetuating,
further enhanced by autocrine type I IFN production by
pDCs and exacerbated by any defect in the clearance of ap-
optotic debris or immune complexes. DNA-containing im-
mune complexes from SLE sera stimulate pDCs to secrete
IFN-  through TLR9 (35, 41, 46). These results demon-
strate that immune complexes upon intracellular delivery
via CD32 can activate pDCs not only through TLR9 as
reported previously (35, 47–49), but also through TLR7,
demonstrating a strong link between the pDCs and autoim-
munity to both DNA- and RNA-containing autoantigens.
Because the snRNAs also have dsRNA regions, we cannot
completely exclude the possibility that they may also stimu-
late TLR3 or other pathogen-associated molecular patterns,
causing additional immune stimulatory effects on cells other
than pDCs (20, 50). But the complete inhibition of the ef-
fects by chloroquine, which fails to block activation by the
TLR3 ligand poly rI:rC, suggests that any such TLR3-medi-
ated effect would be quite small.
Apoptosis may exert additional effects on nucleosomal
material that contribute to the development and direction of
the subsequent autoimmune response. The U1 snRNP in
contrast to other RNPs is only slightly cleaved during apopto-
sis, which could enable the U1 snRNA to better activate the
DCs taking up these particles, resulting in the presentation of
the associated 70K protein and Sm proteins on a mature DC
that might drive a T cell response to the antigens through
epitope spreading. Thus, the RNA component of the sn-
RNPs would act as a built-in adjuvant to drive autoimmune
responses against the associated proteins, explaining their
strong and unique association with systemic autoimmunity.
All of the immune stimulatory effects of the U1 snRNP
or snRNA ORNs are completely blocked by chloroquine at
relatively low concentrations that occur in patients taking
this class of drug for the treatment of SLE. These results sug-
gest that the mechanism of action of chloroquine in the
treatment of systemic autoimmunity, which had been un-
known, could be through inhibition of one or more of
TLR7/8/9. Our data support the concept that chloroquine-
related compounds and suppressive ODNs, which were pre-
viously reported to block DNA-mediated TLR9 stimula-
tion, may prevent apoptotic debris from stimulating and
sustaining autoimmunity. Thus, we have identified a new
potential therapeutic mechanism of action for these agents,
making improved TLR7/8/9 antagonists interesting candidates
for therapeutic development.
MATERIALS AND METHODS
ODNs and reagents. ODNs (Coley Pharmaceutical GmbH) and ORNs
(BioSpring GmbH) were suspended in sterile, endotoxin-free Tris-EDTA
(Sigma-Aldrich) or DNase- and RNase-free dH2O (Life Technologies), re-
spectively. Sequences are listed in Table I. LPS from Escherichia coli and
chloroquine were purchased from Sigma-Aldrich. Recombinant IFN- 2b
(IntronA) was obtained from SP Europe, and poly rI:rC was from GE
Healthcare. R-848 was commercially synthesized by GLSynthesis. U1 sn-
RNP was purchased from Sweden Diagnostic (gel of the preparation used is
shown in Fig. 1 B). U1 snRNA was extracted from U1 snRNPs affinity pu-
rified from K562 cells as described previously (51). Whole human RNA
was extracted from Jurkat cells (American Type Culture Collection LGC
Promochem) with the RNeasy Kit (QIAGEN).
Isolation of cells and cell culture. Peripheral blood buffy coat prepara-
tions from healthy male and female human donors were obtained from the
Institute for Hemostaseology and Transfusion Medicine of the University
Hospital of Düsseldorf as described previously (31). pDCs and monocytes
were isolated with the BDCA-4 pDC or CD14 monocyte isolation kit
(Miltenyi Biotec). mDCs were isolated with the BDCA-1 (CD1c) mDC
isolation kit after depleting CD19  B cells (Miltenyi Biotec). Purity was
confirmed by staining with mAb to CD11c (Diaclone), CD14, HLA-DR,
and CD123 (all from BD Biosciences) and was typically  80%. Purity of
mDC fractions was confirmed by staining with mAb to CD14, CD19, and
streptavidin. Antibody to CD80, CD16, and CD32 (PE labeled) was from
BD Biosciences, and unlabeled blocking antibody to CD32 was from Cell-
Systems Biotechnologie Vertrieb GmbH. For some of the assays, PBMCs
were precultured at 37 C for 4 h with recombinant IFN- 2b before adding
stimulatory substances. SLE patient serum was obtained at the Rheumatol-
ogy Clinic, University of Florida, under a protocol approved by the institu-
tional review board. Murine DCs were derived from Flt3L-induced bone
marrow cultures from C57/B6 wild-type or TLR7 /  mice (protocol ap-
proved by the Munich Institute for Medical Microbiology Animal Use
Committee) as described previously (15).
Reporter gene assay. HEK293 cells bearing a luciferase gene under the
control of a 6 NF- B promoter construct and additionally constitutively
expressing the gene for human TLR8 (“hTLR8-HEK293”; reference 21)
were incubated for 16 h at 37 C in a humidified incubator with reagents asRNA-MEDIATED TLR ACTIVATION | Vollmer et al. 1584
indicated. Cells were lysed and the amount of luciferase was determined
with BriteLite on a luminometer (both from PerkinElmer).
Cytokine detection. Human or murine cells were added to 96-well
round-bottomed plates with or without the addition of TLR ligands or re-
agents as indicated. Enhanced stability and intracellular delivery of U1 sn-
RNP, RNA, or ORN was achieved by DOTAP (Roche) at concentrations
ranging from 5 to 50  g/ml (snRNP typically with 25  g/ml DOTAP). In
some experiments, snRNP or poly rI:rC was pretreated with RNase A or
proteinase K (both from QIAGEN). Culture supernatants were collected at
24 h or at the indicated time points. Amounts of cytokines in the culture
supernatants were assessed using commercially available ELISA kits (human
TNF-  from Diaclone; human and mouse IL-12p40 and mouse TNF- 
from BD Biosciences) or an in-house ELISA developed using commercially
available antibodies (for detection of human or murine IFN- ; PBL Bio-
medical Laboratories).
Immunoprecipitation. K562 cells were cultured overnight with [35S]me-
thionine/cysteine and the proteins were extracted, mixed with 5  l of the pa-
tient serum, and incubated with protein A sepharose beads followed by wash-
ing of the beads, protein gel electrophoresis, and autoradiography.
Online supplemental material. Conserved U-rich motifs within U sn-
RNA and hY RNA are shown in Table S1, which is available at http://
www.jem.org/cgi/content/full/jem.20051696/DC1.
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